Kailera Therapeutics (NASDAQ:KLRA) Sets New 12-Month Low - Time to Sell?

Key Points

• Kailera Therapeutics shares fell to a new 52-week low of $10.20, down 4.5%, with the stock trading well below its 50-day moving average of $15.66.
• The company reported a quarterly loss of $1.09 per share, missing analysts’ estimate of $0.74, and analysts expect a full-year loss of $3.89 per share.
• Despite the weak performance, institutional investors—including Atlas Venture, Wellington Management, and State Street—recently established sizable positions, while analysts maintain a “Moderate Buy” consensus and an average price target of $42.75.

Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report)'s share price reached a new 52-week low on Monday. The stock traded as low as $10.20 and last traded at $10.20, with a volume of 51759 shares. The stock had previously closed at $10.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings started coverage on Kailera Therapeutics in a report on Friday, August 14th. They set a "sell (d)" rating for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Kailera Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $42.75.

Kailera Therapeutics Stock Down 4.5%

The company has a market capitalization of $1.29 billion and a PE ratio of -0.00. The business has a 50-day simple moving average of $15.66.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). Equities analysts anticipate that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KLRA. Frazier Life Sciences Management L.P. acquired a new stake in shares of Kailera Therapeutics during the second quarter worth $24,233,000. State Street Corp acquired a new stake in Kailera Therapeutics in the 2nd quarter worth about $19,126,000. Atlas Venture Life Science Advisors LLC acquired a new stake in Kailera Therapeutics in the 2nd quarter worth about $113,923,000. Wellington Management Group LLP bought a new stake in Kailera Therapeutics in the 2nd quarter valued at about $64,308,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Kailera Therapeutics during the 2nd quarter worth approximately $993,000.

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company's research is centered on therapies designed to address weight management and related health conditions.

Kailera's pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.